Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Controversies in nomenclature: From nonalcoholic steatohepatitis to the full spectrum of hepatic steatosis

  • Romero-Gómez, Manuel
  • Ferretti, Sebastián
  • Arab, Juan Pablo
[EN] The proposal for a nomenclature changes stems from the inaccuracy of the original term, as well as on the absence of any allusion to metabolic disorders and the stigma generated by the use of the terms “nonalcoholic” and “fatty”. The term thus proposed a change from basing its definition on the existence of a histological lesion typical of alcohol damage in the absence of significant alcohol consumption to being defined by the presence of hepatic steatosis demonstrated through biopsy or imaging methods associated with cardiometabolic risk factors, such as diabetes, obesity, arterial hypertension or dyslipidemia in the absence of pathological alcohol consumption. This change has made it possible to define hepatic steatosis as a disease attributed to metabolic disorder and alcohol. This proves the specific similarities and differences between metabolic hepatic steatosis and alcoholic hepatic steatosis, both in their pathogenesis and in the role of genetics and the intestine-liver axis, as well as in potential therapeutic options such as resmetirom or semaglutide. Likewise, this change has made it possible to classify other specific and rare causes of hepatic steatosis, such as hepatotoxicity, immunogenic diseases, hepatitis C or celiac disease., [ES] La propuesta de cambio de nomenclatura encontraba su razón de ser en la inexactitud del término original, así como en la ausencia de alusión a los trastornos metabólicos que conforman su esencia y al estigma que genera el uso tanto del término «no alcohólico», como del de «graso» (fatty en inglés o gordura en portugués). El término pasó de basar su definición en la existencia de una lesión histológica típica del daño por alcohol en ausencia de consumo significativo a definirse a partir de la presencia de esteatosis hepática demostrada por biopsia o métodos de imagen asociados a factores de riesgo cardiometabólicos, como la diabetes, la obesidad, la hipertensión arterial o la dislipemia en ausencia de consumo patológico de alcohol. Este cambio de la nomenclatura ha permitido definir una nueva entidad, la esteatosis hepática por trastorno metabólico y alcohol (EHmet-ALD) que muestra similitudes y diferencias específicas tanto con la esteatosis hepática metabólica (EHmet) como con la esteatosis hepática alcohólica (EHalc) tanto en la patogenia como en el papel de la genética y el eje intestino-hígado como en las potenciales opciones terapéuticas como resmetirom o semaglutida. De la misma forma, este cambio ha permitido ordenar otras causas específicas y poco frecuentes de esteatosis hepática como la hepatotoxicidad, enfermedades monogénicas, la hepatitis C o la enfermedad celíaca., With thanks to the Research Project PI2201342., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Advancing precision medicine in metabolic dysfunction-associated steatotic liver disease

  • Priego-Parra, Bryan Adrián
  • Gallego-Durán, Rocío
  • Román-Calleja, Berenice M.
  • Velarde-Ruiz Velasco, José Antonio
  • Romero-Gómez, Manuel
  • Gracia-Sancho, Jordi
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), has become a pressing global health concern. The complexity of MASLD and the lack of universally effective treatments expose the limitations of current interventions, which focus mainly on lifestyle modifications. Here, we explore the multilayered nature of MASLD, emphasizing its pathophysiology in shaping future medical and lifestyle interventions from a personalized medicine perspective, based on individual molecular profiles. Additionally, we address the limitations of current animal models in reflecting human metabolic syndrome and sex-specific differences. We argue that a holistic approach, integrating social determinants of health, patient preferences, and adherence patterns, is essential for advancing MASLD management effectively., Authors acknowledge continuous funding from the Instituto de Salud Carlos III (ISCIII; currently PI23/00945, DTS22/00010 & DTS24/00035 to J.G.-S., CD21/00095, PI22/01342, PI22/01345 and PI24/02008 to R.G.-D. and M.R.-G., all co-funded by the European Union), the AGAUR-Generalitat de Catalunya (2021 SGR 01322 & 2021 PROD 00036) to J.G.-S and the CIBEREHD. CIBEREHD is funded by the Instituto de Salud Carlos III., Peer reviewed